← 返回

CD8⁺ T 细胞的昼夜节律性肿瘤浸润和功能决定免疫治疗疗效

英文原题:Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy.

查看英文原题

Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy.

PubMed 2024/05/08(内容时间) Cell Q1 · IF 45.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

TIL(肿瘤浸润淋巴细胞)的数量和质量,尤其是 CD8+ T 细胞,是控制肿瘤生长和免疫治疗应答的重要参数。本研究在小鼠和人类癌症中显示,这些参数呈昼夜节律振荡,由白细胞内源性生物钟及节律性白细胞浸润共同驱动;后者依赖肿瘤微环境内皮细胞的生物钟。为利用这种节律,研究证明调整治疗时段可改善CAR-T 细胞疗法和免疫检查点阻断的疗效。此外,小鼠肿瘤模型中具有时段依赖性的 T 细胞特征可预测黑色素瘤患者总生存期,并与抗 PD-1 治疗应答相关。数据表明肿瘤微环境昼夜动态具有功能意义,并提示未来临床试验设计和患者照护应充分利用这些特征。

展开英文摘要原文

The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8 + T cells, are important parameters for the control of tumor growth and response to immunotherapy.

Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms therapeutically, we demonstrate that efficacy of chimeric antigen receptor T cell therapy and immune checkpoint blockade can be improved by adjusting the time of treatment during the day.

Furthermore, time-of-day-dependent T cell signatures in murine tumor models predict overall survival in patients with melanoma and correlate with response to anti-PD-1 therapy.

Our data demonstrate the functional significance of circadian dynamics in the tumor microenvironment and suggest the importance of leveraging these features for improving future clinical trial design and patient care.

论文信息

作者
Wang C、Zeng Q、Gül ZM、Wang S、Pick R、Cheng P、Bill R、Wu Y
第一作者单位
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland. Electronic address: chen.wang.1@unige.ch.Switzerland
通讯作者单位
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Translational Research Centre in Onco-Hematology (CRTOH), Geneva 1211, Switzerland; Institute of Genetics and Genomics of Geneva (iGE3), Geneva 1211, Switzerland; Geneva Centre for Inflammation Research (GCIR), Geneva 1211, Switzerland; Biomedical Center (BMC), Institute for Cardiovascular Physiology and Pathophysiology, Walter Brendel Center for Experimental Medicine (WBex), Faculty of Medicine, Ludwig-Maximilians-Universität (LMU) Munich, Planegg-Martinsried 82152, Germany. Electronic address: christoph.scheiermann@unige.ch.Switzerland
期刊
Cell2024 May 23
原文标识
PubMed 38723627 · DOI 10.1016/j.cell.2024.04.015